A look at the science that explains why exercise improves glucose regulation even when insulin cannot.
Abstract
Professor Juleen R. Zierath has spent more than three decades uncovering how exercise reshapes muscle metabolism and why these mechanisms matter for people with obesity or type 2 diabetes. Her work demonstrates that insulin resistance originates in skeletal muscle and that exercise can bypass this defect through alternative pathways that enhance glucose uptake. By connecting molecular biology, circadian timing, gene regulation, and real-world physiology, she has built a foundation for more personalized approaches to metabolic health. Her research offers insight into why movement remains one of the most effective tools for improving glucose regulation and overall metabolic function.
Key Points
Read more: Professor Juleen R. Zierath: Three Decades of Showing How Exercise Changes Metabolism
A plain-language guide to how mRNA works and why it matters for future health care
Abstract
mRNA vaccines work by delivering temporary instructions that help the body produce a harmless protein and build immune protection—without using live viruses or altering DNA. Backed by decades of research, this approach offers a safe, flexible alternative to traditional vaccines. Clear explanations dispel common misconceptions and highlight how mRNA technology could one day support treatments for chronic conditions like type 2 diabetes.
Key Points
I’m pleased to share that I’ve successfully completed Diabetes – A Global Challenge, an online course authorized by the University of Copenhagen and offered through Coursera. The content goes well beyond the basics, covering genetic factors, inflammatory processes, stem cell-based therapies, and the development of antidiabetic agents.
Read more: Successfully Completed: Diabetes – A Global Challenge
Eli Lilly has announced positive phase 3 results for its once-weekly insulin, efsitora alfa (efsitora). This news represents a significant advancement in diabetes management, potentially transforming treatment for millions of people living with type 2 diabetes.
Phase 3 Clinical Trials: QWINT-2 and QWINT-4
Eli Lilly’s phase 3 trials, QWINT-2 and QWINT-4 evaluated the efficacy and safety of efsitora. The QWINT-2 trial compared efsitora to Novo Nordisk’s daily insulin degludec (Tresiba) over 52 weeks in insulin-naïve adults. The trial successfully met its primary endpoint, demonstrating that efsitora was non-inferior (at least as good as) to degludec in reducing HbA1c levels. Efsitora reduced HbA1c by 1.34%, while degludec achieved a 1.26% reduction, resulting in final HbA1c levels of 6.87% and 6.95%, respectively.
The QWINT-4 trial compared efsitora to insulin glargine (Lantus) over 26 weeks in adults previously treated with basal insulin and mealtime insulin. Both treatments reduced HbA1c by 1.07%, demonstrating comparable efficacy. Importantly, efsitora was well-tolerated in both trials, though it did show slightly higher rates of hypoglycemic events compared to the daily insulins. Hypoglycemia is always a possibility for anyone taking insulin.
The Competitive Landscape: Novo Nordisk's Insulin Icodec
Eli Lilly's success with efsitora comes amid fierce competition with Novo Nordisk, another principal producer of insulin. Novo Nordisk's once-weekly insulin, Icodec (Awiqli®), is currently under FDA review, with approval anticipated later this year. Icodec has already demonstrated promising results, achieving superior blood sugar reduction and increased Time in Range compared to daily basal insulins in clinical trials.
Comparing Efsitora Alfa and Icodec
Both efsitora and Icodec aim to reduce the burden of daily injections for people with diabetes, offering a once-weekly alternative. Key comparisons include:
The Future of Diabetes Treatment
Once-weekly insulins like efsitora and Icodec mark a noteworthy advancement in diabetes treatment. These innovations will significantly reduce the daily burden of managing diabetes, potentially improving treatment adherence and health outcomes. As both Eli Lilly and Novo Nordisk continue to innovate in diabetes care, patients can look forward to more convenient and effective treatment options.
With regulatory approvals coming, the future of diabetes management looks brighter than ever.
Frequently Asked Questions
How soon can patients expect to see improvements in their blood sugar levels after starting efsitora alfa?
Patients may begin to see improvements in blood sugar levels within the first few weeks of starting efsitora alfa, as it gradually stabilizes glucose levels over time.
Are there any dietary or lifestyle changes recommended when switching to once-weekly insulin?
No specific dietary or lifestyle changes are required when switching to once-weekly insulin, but maintaining a healthy diet and regular exercise routine is always beneficial for diabetes management.
How do once-weekly insulins affect insulin sensitivity compared to daily insulins?
Once-weekly insulins like efsitora alfa are designed to provide stable insulin levels throughout the week, which may help maintain insulin sensitivity similarly to daily insulins.
How do patients and caregivers feel about switching to once-weekly insulin?
Feedback from patients and caregivers has been positive, highlighting the convenience and reduced injection burden as significant benefits of once-weekly insulin.
How will once-weekly insulins be integrated into existing diabetes treatment guidelines?
Once-weekly insulins are expected to be incorporated into diabetes treatment guidelines as an alternative to daily basal insulins, especially for patients who struggle with adherence to daily injections.
In the realm of medical research, the intersection of space exploration and healthcare innovation is not something that comes up often. A recent public comment by Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk, has sparked interest in a potential new avenue for the study of GLP-1 (glucagon-like peptide-1) and its effects on neuroinflammation, not just from the medical community but also from an unexpected source: NASA.
A Brief Overview of GLP-1
GLP-1 is a hormone involved in glucose metabolism, known for its role in enhancing insulin secretion in response to high blood glucose levels. Its therapeutic potential has been harnessed in the treatment of type 2 diabetes and obesity through GLP-1 receptor agonists. These medications help manage blood sugar levels and promote weight loss. Beyond these well-documented benefits, GLP-1 receptor agonists are also being explored for their neuroprotective properties.
The Connection to Space Exploration
Knudsen's comment sheds light on NASA's interest in GLP-1 for its proposed effect on neuroinflammation. This interest is rooted in the challenges faced by astronauts during deep space missions, including the problem of high blood pressure in the brain. The potential of GLP-1 to alleviate such issues could have significant implications for the health and safety of astronauts, potentially allowing for more extended missions or even habitation in space.
The Implications for Type 2 Diabetes and Obesity Care
The exploration of GLP-1's effects on neuroinflammation opens new research avenues that could benefit patients with type 2 diabetes and obesity. Neuroinflammation is a critical factor in the development and progression of various neurological conditions. If GLP-1 can effectively reduce neuroinflammation, it may offer protective benefits against neurodegenerative diseases, which are of particular concern for individuals with diabetes and obesity due to their increased risk.
The Future of GLP-1 Research
The interest from NASA may catalyze further studies into the neuroprotective effects of GLP-1 and its potential applications beyond diabetes and obesity care. This could lead to the development of GLP-1-based therapies targeting neuroinflammation and possibly preventing or mitigating the effects of neurodegenerative diseases. For patients with type 2 diabetes and obesity, this research could offer new hope for treatments that address not only their metabolic conditions but also protect against neurological complications.
Additionally, the recent FDA approval of the GLP-1 medication Wegovy for reducing the risk of major adverse cardiovascular events, such as cardiovascular death, heart attack, and stroke, underscores the expanding therapeutic scope of GLP-1 receptor agonists and their potential to offer multiple benefits to patients.
Summary
The comment made by Lotte Bjerre Knudsen highlights an exciting intersection of space exploration and medical research, with GLP-1 at the center of potential breakthroughs in neuroinflammation and beyond. As we look to the stars, we may also find new ways to improve health and well-being here on Earth, particularly for those living with type 2 diabetes and obesity. The journey of GLP-1 from a glucose-regulating hormone and cardioprotective agent to a possible neuroprotective agent for astronauts exemplifies the almost limitless possibilities of medical research and its impact on diverse fields, including the final frontier of space.
Frequently Asked Questions
What specific neurological conditions could potentially benefit from GLP-1-based therapies?
Conditions such as Alzheimer's, Parkinson's, and stroke-related neurodegeneration could potentially benefit from GLP-1-based therapies due to their involvement with neuroinflammatory processes.
How does the effect of GLP-1 on neuroinflammation compare to its effects on glucose metabolism and weight loss?
While GLP-1's effects on glucose metabolism are well-established, its impact on neuroinflammation is a newer area of research, and studies are ongoing to understand its comparative effectiveness.
How are astronauts currently managing the problem of high blood pressure in the brain during space missions?
Astronauts currently manage high brain blood pressure through various methods, including medication and physical exercise, but research into GLP-1 could offer more targeted solutions.